Urine lipoarabinomannan to monitor antituberculosis therapy response and predict mortality in an HIV-endemic region:A prospective cohort study

BMJ Open

Volumn 5, Issue 4, 2015, Pages

  Drain, Paul K ^a,b   Gounder, Lilishia ^c   Grobler, Anneke ^d   Sahid, Faieza ^e   Bassett, Ingrid V ^a,b   Moosa, Mahomed Yunus S ^f  

^a Medical Practice Evaluation Center   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c INKOSI ALBERT LUTHULI CENTRAL HOSPITAL   (South Africa)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; LIPOARABINOMANNAN; BIOLOGICAL MARKER; LIPOPOLYSACCHARIDE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; COHORT ANALYSIS; COUGHING; DRUG MONITORING; FEMALE; FEVER; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KARNOFSKY PERFORMANCE STATUS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NIGHT SWEAT; OUTPATIENT DEPARTMENT; PATIENT REFERRAL; PREDICTION; PROSPECTIVE STUDY; SOUTH AFRICA; SPUTUM; TERTIARY CARE CENTER; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS; WEIGHT REDUCTION; CD4 LYMPHOCYTE COUNT; COMPLICATION; ENDEMIC DISEASE; EVALUATION STUDY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; LONGITUDINAL STUDY; MASS SCREENING; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT; PHYSIOLOGIC MONITORING; PROCEDURES; TUBERCULOSIS, PULMONARY; URINE;

ADULT; ANTITUBERCULAR AGENTS; BIOMARKERS; CD4 LYMPHOCYTE COUNT; ENDEMIC DISEASES; FEMALE; HIV; HIV INFECTIONS; HUMANS; LIPOPOLYSACCHARIDES; LONGITUDINAL STUDIES; MALE; MASS SCREENING; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; PATIENT OUTCOME ASSESSMENT; PROSPECTIVE STUDIES; SOUTH AFRICA; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 84929327949     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006833     Document Type: Article

References (30)

1. World Health Organization. Global TB Report 2012. Geneva: World Health Organization, 2012.
2. World Health Organization. Joint TB/HIV Interventions. Geneva: World Health Organization, 2009.
3. Getahun H, Harrington M, O'Brien R, et al. Diagnosis of smear negative pulmonary tuberculosis in people with HIV infection or AIDS in resource constrained settings: informing urgent policy changes. Lancet 2007;369:2042-9.
4. Wallis RS, Pai M, Menzies D, et al. Biomarker and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010;375:1920-37.
5. Dye C, Watt CJ, Bleed DM, et al. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. J Amer Med Assoc 2005;293:2767-75.
6. Keeler E, Perkins MD, Small P, et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature 2006;444(Suppl 1):49-57.
7. Horne DJ, Royce SE, Gooze L, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis 2010;10:387-94.
8. World Health Organization Global Tuberculosis Programme. Treatment of Tuberculosis guidelines. 4th edn. Geneva: World Health Organization, 2010.
9. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010;363:1005-15.
10. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011;8:e1001067.
11. Miotto P, Bigoni S, Migliori GB, et al. Early tuberculosis treatment monitoring by Xpert MTB/Rif. Euro Resp J 2013;39:1269-71.
12. Hamasur B, Bruchfeld J, Haile M, et al. Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine. J Micro Methods 2001;45:41-52.
13. Sahid F, Thumbiran NV, Gounder L, et al. Diagnosis of smear negative HIV associated pulmonary tuberculosis: a comparison of sputum obtained by a novel intra-oesophageal device with induced sputum. Seattle: Conference on Retroviruses and Opportunistic Infections, 2012.
14. World Health Organization. Systematic screening for active tuberculosis: principles and recommendations. Geneva: World Health Organization, 2013 (WHO/HTM/TB/2013.04).
15. National Department of Health, Republic of South Africa. Clinical guidelines for the management of HIV & AIDS in adults and adolescents. South Africa: Department of Health, 2010.
16. Alere Inc. Determine™ TB LAM test. Waltham, USA. http://www.alere.com/au/en/product-details/determine-tb-lam.html (accessed 22 Mar 2013).
17. Drain PK, Gounder L, Grobler A, et al. Point-of-Care Urine Lipoarabinomannan (LAM) for Diagnosis and Treatment Response of Pulmonary Tuberculosis in Sputum Smear-Negative Suspects. 44th Union World Conference on Lung Health on November 2, 2013.
18. Peter JG, Theron G, van Zyl Smit R, et al. Diagnostic accuracy of a urine LAM strip-test for TB detection in HIV-infected hospitalized patients. Eur Respir J 2012;40:1211-20.
19. Dorman S, Manabe Y, Nicol M, et al. Accuracy of Determine TB-Lipoarabinomannan lateral flow test for diagnosis of TB and HIV+ adults: Interim results from a multicenter study. Abstract of the 19th Conference on Retroviruses and Opportunistic Infection. Seattle, WA, 2012. Abstract #149aLB.
20. Shah M, Ssengooba W, Armstrong D, et al. Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals. AIDS 2014;28:1307-14.
21. Nakiyingi L, Moodley VM, Manabe YC, et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr 2014;66:270-9.
22. Balcha TT, Winqvist N, Sturegard E, et al. Detection of lipoarabinomannan in urine for identification of active tuberculosis among HIV-positive adults in Ethiopian health centres. Trop Med Int Health 2014;19:734-42.
23. Avorn J. Approval of a tuberculosis drug based on a paradoxical surrogate measure. J Am Med Assoc 2013;309:1349-50.
24. Johnson JL, Hadad DJ, Dietze R, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 2009;180:558-63.
25. Epstein MD, Schluger NW, Davidow AL, et al. Time to detection of Mtb tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest 1998;113:379-86.
26. Wallis RS, Perkins M, Phillips M, et al. Induction of the antigen 85 complex of M. tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis. J Infect Dis 1998;178:1115-21.
27. Davies GR, Brindle R, Khoo SH, et al. Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrob Agents Chemother 2006;50:3154-6.
28. Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the Diarylquinoline TMC 207 in pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52:2831-5.
29. Dorman S, Manabe Y, Nicol M, et al. Accuracy of Determine TB-Lipoarabinomannan lateral flow test for diagnosis of TB and HIV+ adults: Interim results from a multicenter study. 19th Conference on Retroviruses and Opportunistic Infection. Seattle, 2012. Abstract #149aLB.
30. Boshoff HI, Barry CE III. Tuberculosis - metabolism and respiration in absence of growth. Nat Rev Microbiol 2005;3:70-80.